Fluoroquinolones: Drug Interactions and Clinical Uses

Your slides cover two related pharmacology topics for the fluoroquinolone class (ciprofloxacin, levofloxacin, moxifloxacin, etc.). Here's the full explanation with mechanisms filled in, since the slides list the interactions but don't explain why they happen.

1. Drug Interactions

A. Interactions affecting fluoroquinolone levels/toxicity

Co-administered drug	Effect	Mechanism
Theophylline	Fluoroquinolones (especially ciprofloxacin) raise theophylline plasma levels	Ciprofloxacin strongly inhibits CYP1A2, the enzyme that metabolizes theophylline. This can precipitate theophylline toxicity (nausea, arrhythmias, seizures)
NSAIDs	Increased risk of CNS toxicity (seizures) when combined with fluoroquinolones	This is a pharmacodynamic, not pharmacokinetic, interaction: both fluoroquinolones and NSAIDs antagonize GABA-A receptors, and the combination lowers seizure threshold - a known cause of fluoroquinolone-induced convulsions, per Goodman & Gilman's Pharmacological Basis of Therapeutics
Corticosteroids	Increased risk of tendinopathy and tendon rupture (especially Achilles tendon), particularly in elderly patients	Not a plasma-level interaction - it's additive risk of collagen/tendon damage. This combination (and renal transplant patients) is the classic high-risk group for fluoroquinolone-associated tendon rupture

Note: the slide groups these three together as "drugs that increase fluoroquinolone levels," but only theophylline truly has that kind of kinetic relationship (and even then, it's really the fluoroquinolone raising theophylline levels via CYP1A2, not the other way around). NSAIDs and corticosteroids are clinically important co-administration risks, just via different mechanisms (seizure risk and tendon risk, respectively) rather than serum-level changes.

B. Fluoroquinolones increasing levels of other drugs

Ciprofloxacin (the strongest CYP1A2 inhibitor of the class) raises plasma concentrations of:

Theophylline - risk of toxicity (tremor, seizures, arrhythmia)
Caffeine - reduced clearance, exaggerated CNS stimulant effects
Warfarin - potentiates anticoagulant effect, raising INR and bleeding risk (via CYP interaction plus possible reduction of gut-flora vitamin K synthesis)
Antidepressants (e.g., imipramine) - increased tricyclic levels via CYP inhibition, raising risk of cardiotoxicity/CNS effects

Confirmed in Harrison's Principles of Internal Medicine (Table 149-3, Important Antibacterial Drug Interactions) and Goodman & Gilman's, which both list theophylline and warfarin as key substrates affected by fluoroquinolone CYP inhibition.

C. Antacids and iron salts - reduced fluoroquinolone absorption

Multivalent cations (Al³⁺, Mg²⁺ in antacids, Ca²⁺, Fe²⁺/Fe³⁺ in iron salts, and also zinc, sucralfate, dairy products) chelate with the fluoroquinolone molecule in the gut, forming an insoluble complex that cannot be absorbed. This can reduce fluoroquinolone bioavailability enough to cause treatment failure.

Clinical fix: separate dosing - take the fluoroquinolone at least 2 hours before or 6 hours after the antacid/iron/multivalent cation, as noted in Dermatology 2-Volume Set's drug interaction table.

2. Clinical Uses of Fluoroquinolones

Anthrax: Ciprofloxacin is a first-line drug for both prophylaxis and treatment of anthrax (inhalational anthrax specifically is treated with a fluoroquinolone plus a second agent such as a protein synthesis inhibitor or carbapenem), per Fishman's Pulmonary Diseases and Goldman-Cecil Medicine.
UTIs, urethritis, cervicitis: Ciprofloxacin and levofloxacin are effective for both uncomplicated and complicated urinary tract infections - they achieve high urinary concentrations, per Katzung's Basic and Clinical Pharmacology.
GI infections: Ciprofloxacin is highly effective for acute diarrheal illness from enteric pathogens (e.g., traveler's diarrhea, some Salmonella/Shigella/Campylobacter infections).
Respiratory infections: Levofloxacin and moxifloxacin are called "respiratory fluoroquinolones" because they have enhanced activity against Streptococcus pneumoniae and atypical organisms, making them useful for upper and lower respiratory tract infections (URTIs/LRTIs, community-acquired pneumonia).
Osteomyelitis: Ciprofloxacin and levofloxacin penetrate bone well and can be given orally, making them a preferred option for bone infections due to Gram-negative bacilli (e.g., Pseudomonas aeruginosa) - confirmed by Katzung's, which lists osteomyelitis as a key indication for ciprofloxacin.
Diabetic foot infections: Moxifloxacin, a broad-spectrum fourth-generation agent, covers both aerobic and anaerobic organisms commonly seen in diabetic foot infections.
Tuberculosis/atypical mycobacteria: Ciprofloxacin, levofloxacin, or moxifloxacin are occasionally used (moxifloxacin and levofloxacin have more established roles, particularly in drug-resistant TB regimens).
Meningococcal carriage eradication: Fluoroquinolones (notably ciprofloxacin as a single dose) can be used for eradicating meningococci from nasopharyngeal carriage in contacts.

Key takeaway

The unifying theme: fluoroquinolones (especially ciprofloxacin) are potent CYP1A2 inhibitors, which explains most of the drug-level interactions (theophylline, caffeine, warfarin, tricyclics), while their chelation with multivalent cations explains the antacid/iron absorption problem, and their excellent tissue penetration (bone, urine, lung) explains their broad clinical utility in bone, urinary, respiratory, and GI infections, plus their special role in anthrax and biodefense scenarios.

This is a shared conversation. Sign in to Orris to start your own chat.